NCT01585688 2021-10-08
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
Gilead Sciences
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT00989586 2017-02-06
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00868478 2010-06-02
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Kaplan Medical Center
Phase 1/2 Unknown